The short answer
Of the 68 compounds in our encyclopedia, one has hair growth described as a research use: GHK-Cu, a copper-binding tripeptide. The human evidence we cite for it supports topical use on skin, for healing. We do not cite a human trial of GHK-Cu for hair growth, so hair growth is a use it is studied for, not an established result.
None of the peptides on our tier list is approved for hair loss. Two approved ones list hair loss as a side effect, which is covered below.
Peptides studied for hair growth
Tiers come from our peptide tier list, where S means FDA-approved and D means the evidence is mostly animal and laboratory studies. More rows will appear here only when a compound's own research covers hair.
| Peptide and evidence tier | What the research is | Route studied | Key source |
|---|---|---|---|
| GHK-CuTier B · Some human evidence | Studied for wound healing, collagen synthesis, skin rejuvenation and hair growth. The human evidence we cite supports topical use for skin healing; we cite no human trial of it for hair growth. | Topical in human studies; injected use studied far less formally | Review, 2008 |
Approved peptides that list hair loss as a side effect
Hair also comes up in the other direction. Two FDA-approved compounds in our encyclopedia report hair loss among their adverse reactions.
- Orforglipron (tier S). The Foundayo label lists hair loss among the most common adverse reactions, reported in at least 5% of patients.
- Pentosan Polysulfate (tier S). The Elmiron prescribing information lists alopecia (hair loss) among the reported adverse reactions.
What this doesn’t tell you
Studied for is not shown to. A compound being studied for hair growth means researchers are looking at it. It does not mean trials have found that it regrows hair.
Topical and injected are different questions. The human evidence for GHK-Cu is for applying it to the skin. Research-grade GHK-Cu is also sold as a powder vial for injection, a route that has been studied far less formally.
Blends are not tested. GLOW, a vial of GHK-Cu with BPC-157 and TB-500, is marketed for skin, hair and recovery. No published study has tested the combination. Our blends guide covers what is in it.
Hair loss has several causes. Patterned, stress-related and medication-related hair loss are different conditions, which is one reason a clinician's assessment matters more than any compound list.
Sources
- The human tri-peptide GHK and tissue remodeling. Pickart L et al. Journal of Biomaterials Science, Polymer Edition, 2008. Review
- FOUNDAYO (orforglipron) tablets, for oral use - Highlights of Prescribing Information. U.S. Food and Drug Administration, 2026. Fda label
- ELMIRON (pentosan polysulfate sodium) capsules - Prescribing Information. U.S. Food and Drug Administration, 2021. Fda label
Frequently asked questions
Which peptides are studied for hair growth?
In our encyclopedia, GHK-Cu is the only peptide whose research covers hair growth. Its human evidence supports topical use on skin, and we cite no human trial of it for hair growth.
Does GHK-Cu regrow hair?
That has not been shown in the human research we cite. Hair growth is a use GHK-Cu is studied for, and its human evidence is for topical use on skin healing.
Is any peptide FDA-approved for hair loss?
None of the peptides on our evidence tier list is approved for hair loss.
Can peptides cause hair loss?
Some approved ones list it as a side effect. The Foundayo (orforglipron) label lists hair loss among its most common adverse reactions, and the Elmiron (pentosan polysulfate) prescribing information lists alopecia.
What is the GLOW peptide?
A blend sold as GHK-Cu, BPC-157 and TB-500 in one vial and marketed for skin, hair and recovery. No published study has tested the combination.
Look up any compound in the app
PeptidesAI covers 70 compounds with the same evidence-first approach, plus a reconstitution calculator, a dose log and reminders. Free to download on iPhone.
Download on the App Store